Abstract: The present invention relates to methods for deriving multipotent Isl1+ cells (i.e. methods for inducing a cell to enter a multipotent Isl1+ lineage), methods for differentiating Isl1+ cells to cardiac cells, cells obtainable by such methods, kits and compositions for carrying out the methods in accordance with the invention, and also medical applications and pharmaceutical compositions of said cells.
Type:
Grant
Filed:
March 11, 2019
Date of Patent:
March 21, 2023
Assignee:
Swedish StromaBio AB
Inventors:
Karl Henrik-Grinnemo, Oscar Simonson, Matthias Corbascio, Christer Sylvén, Eva Wärdell
Abstract: The present invention relates to pharmaceutical compositions comprising mesenchymal cells (MSCs) and additional agents for blocking co-stimulation of the immune system. The compositions may optionally further comprise a therapeutic cell, a therapeutic tissue, and/or a therapeutic organ implant. Additionally, the instant invention pertains to medical uses of such compositions in immune-mediated diseases and disorders, in essentially all inflammatory and/or autoimmune diseases and conditions, and also in transplantation-related conditions.